UPS allocates $48 million towards cold chain development in response to the increasing demand for biologics.

      UPS is committing $48 million to establish 27 temperature-controlled freight facilities across the Americas, Europe, and Asia in response to the growing demand for biologics and GLP-1 medications that are transforming pharmaceutical logistics. The company aims to achieve $20 billion in healthcare revenue by the end of 2026.

      The new facilities will serve as short-term storage points for air and ground transport, ensuring specific temperature requirements of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius, and sub-zero conditions are maintained, as stated by the company.

      This investment is part of UPS's larger strategic shift to create a real-time digital twin of its logistics network and encompasses billions spent on acquisitions to establish itself as a leader in complex healthcare logistics. The company anticipates that healthcare will account for about 18 percent of its total sales by 2026.

      The importance of cold chain logistics has become increasingly significant as the pharmaceutical sector moves towards temperature-sensitive drugs. Currently, about one-third of newly approved medications are biologics, with over 85 percent requiring temperature-controlled environments, according to PharmaSource.

      The market for temperature-sensitive biologics is expected to grow at a compound annual growth rate of 8.3 percent until 2033, potentially reaching $39.1 billion, driven primarily by GLP-1 injectables like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, along with developments in cell and gene therapies, and mRNA technologies.

      Cold chain failures pose a significant financial risk, with industry estimates suggesting that the global cost of temperature mismanagement could be as high as $35 billion each year. Additionally, the World Health Organization has claimed that inadequate temperature control could lead to up to 50 percent of global vaccine waste.

      “We have aligned our investments with the specialized requirements of our healthcare clients,” commented Kate Gutmann, executive vice president and president of international, healthcare, and supply chain solutions at UPS. “Our goal is to facilitate patient access to essential medications and treatments.”

      The expansion of cross-dock facilities builds on strategic acquisitions that have repositioned UPS Healthcare from a peripheral operation to a central growth driver. For instance, UPS invested $1.6 billion to acquire Canada’s Andlauer Healthcare Group in 2025, enhancing its cold chain transportation capabilities across North America.

      Prior acquisitions included Italy’s Bomi Group, which contributed temperature-controlled facilities across 14 countries and added over 350 refrigerated vehicles, as well as European cold chain providers Frigo Trans and BPL. UPS also extended its Incheon air hub in South Korea, a market that imported nearly $9.7 billion in pharmaceutical products in 2025.

      Now, UPS Healthcare operates 19.2 million square feet of cGMP and GDP-compliant distribution space worldwide. The unit recorded its first $3 billion revenue quarter in the first quarter of 2026, positioning it to reach the $20 billion annual revenue goal set by CEO Carol Tomé when she prioritized healthcare as the company's main strategic focus.

      With the pharmaceutical industry pipeline indicating heightened demand, especially as AI-developed therapies and digital patient pathways make more temperature-sensitive treatments available, parcel companies capable of maintaining strict temperature conditions—like 4 degrees Celsius from a factory in Basel to a clinic in Seoul—will have established a logistical advantage that is challenging to replicate.